A practical reference on freeze–thaw cycle: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-01 and is reviewed periodically as new material appears.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatographic profiles reveal related impurities, truncated sequences, and oxidation products, while mass measurement confirms the expected molecular mass. Purity values for research material are typically reported as a percentage by peak area. Reference standards help calibrate retention behavior across instruments. Independent laboratories emphasize method suitability because results depend heavily on column chemistry, gradient, and detection wavelength. Batch-to-batch comparison relies on the same validated method.
Investigational peptide material is commonly distributed as a lyophilized powder in sealed vials. The solid form appears as a white to off-white cake or powder and is hygroscopic once opened. Peptides of this size are sensitive to moisture, repeated freeze-thaw cycles, and prolonged exposure to ambient light. Handling practices therefore emphasize desiccation, minimal vial opening, and cold storage. Working aliquots are often prepared to avoid repeatedly warming the bulk container.
Solid material is generally held at -20 °C or colder, while reconstituted solutions are kept at 2-8 °C and used within a short window. Buffers that maintain a slightly acidic to neutral pH tend to improve short-term peptide stability. Repeated warming and cooling of stock solutions promotes aggregation and should be avoided. Container closures should remain intact, since adsorption to some plastics can reduce the amount of peptide in solution.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | Designed to engage three receptor targets |
| Appearance | White to off-white powder | Lyophilized form supplied in sealed vials |
| Solubility | Soluble in water | Dissolves in aqueous buffer systems |
| Storage, solid | -20 °C or below | Desiccated and protected from light |
| Typical analysis | RP-HPLC with mass detection | Purity by peak area, identity by mass |
Characterization panels may add amino acid analysis for compositional confirmation, circular dichroism for secondary structure in solution, and light scattering for aggregation tendency. Aggregation is a central concern for peptides bearing hydrophobic side chains, since it can lower measured potency and complicate accurate dosing. Stability studies examine temperature, humidity, pH, and light exposure over defined intervals, reporting the percentage of intact peptide remaining. Results depend strongly on the assay used, so comparing values across studies requires matching method details.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.
Identification and purity assessment typically rely on reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Mass measurement confirms the expected molecular mass and can reveal truncations or modifications. Peptide mapping and sequencing techniques provide sequence-level confirmation when needed. Because related peptide impurities can behave similarly in a single method, orthogonal techniques are usually combined. Reported purity values depend heavily on the method used and should be interpreted with that in mind.
Dissolution behavior depends on the amino acid sequence, the counterion content, and the buffer chosen. Many peptides disperse readily in water or mild aqueous buffers, while others require a small amount of organic co-solvent or a change in pH. Adsorption to plastic and glass surfaces can reduce the concentration of a solution over time, particularly at low concentrations. Filtration before analysis removes particulates, and aliquoting limits repeated freeze-thaw cycles that stress the material.
Research-grade peptide material is commonly supplied as a lyophilized powder, a form that limits degradation during transport and storage. Standard practice keeps such material cold and protected from light and moisture, with tighter conditions used for long-term archives. Once dissolved, solutions are generally considered less stable than the dry powder and are handled on shorter timescales. These established conventions derive largely from general peptide chemistry rather than from compound-specific evidence alone.
Retatrutide is handled in laboratories mainly as a lyophilized solid for analytical and biochemical research. The peptide is typically supplied as a white to off-white powder and is reconstituted in appropriate solvents before use. Because peptide-based molecules are sensitive to temperature, moisture, and repeated freeze-thaw cycles, proper storage conditions affect both stability and measurement accuracy. Laboratories generally follow documented handling procedures to maintain the integrity of the material across experiments.
Identification and purity assessment rely on established analytical techniques. Reverse-phase high-performance liquid chromatography separates the compound from related impurities and degradation products. Mass spectrometry confirms molecular identity and detects modifications that change the expected mass. Additional methods such as amino acid analysis or capillary electrophoresis may be used for verification. Small differences in sample preparation can influence results, so procedures are usually controlled and documented in detail. Consistency between runs supports confidence in reported values.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
=== Neuromorphic computer chips === Neuromorphic engineering is a branch of neuroscience that deals with creating functional physical models of neurons for the purposes of useful computation. The emergent computational properties of neuromorphic computers are fundamentally different from conventional computers in the sense that they are complex systems, and that the computational components are interrelated with no central processor.One example of such a computer is the SpiNNaker supercomputer. Sensors can also be made smart with neuromorphic technology. An example of this is the Event Camera's BrainScaleS (brain-inspired Multiscale Computation in Neuromorphic Hybrid Systems), a hybrid analog neuromorphic supercomputer located at Heidelberg University in Germany. It was developed as part of the Human Brain Project's neuromorphic computing platform and is the complement to the SpiNNaker supercomputer, which is based on digital technology. The architecture used in BrainScaleS mimics biological neurons and their connections on a physical level; additionally, since the components are made of silicon, these model neurons operate on average 864 times (24 hours of real time is 100 seconds in the machine simulation) that of their biological counterparts. Recent advances in neuromorphic microchip technology have led a group of scientists to create an artificial neuron that can replace real neurons in diseases.
Iodine-129 (129I; half-life 16.1 million years) is a product of cosmic ray spallation on various isotopes of xenon in the atmosphere, in cosmic ray muon interaction with tellurium-130, and also uranium and plutonium fission, both in subsurface rocks and nuclear reactors. Artificial nuclear processes, in particular nuclear fuel reprocessing and atmospheric nuclear weapons tests, have now swamped the natural signal for this isotope. Nevertheless, it now serves as a groundwater tracer as indicator of nuclear waste dispersion into the natural environment. In a similar fashion, 129I was used in rainwater studies to track fission products following the Chernobyl disaster. In some ways, 129I is similar to 36Cl. It is a soluble halogen, exists mainly as a non-sorbing anion, and is produced by cosmogenic, thermonuclear, and in-situ reactions. In hydrologic studies, 129I concentrations are usually reported as the ratio of 129I to total I (which is virtually all 127I). As is the case with 36Cl/Cl, 129I/I ratios in nature are quite small: the pre-nuclear ratio was nearly 10−12, but as mentioned artificial sources are normally now much greater. 129I differs from 36Cl in that its half-life is longer (16.1 vs. 0.301 million years), it is highly biophilic, and occurs in multiple ionic forms (commonly, I− and IO3−), which have different chemical behaviors. This makes it fairly easy for 129I to enter the biosphere as it becomes incorporated into vegetation, soil, milk, animal tissue, etc.
Relugolix is a selective antagonist of the gonadotropin-releasing hormone receptor (GnRHR), with a half-maximal inhibitory concentration (IC50) of 0.12 nM. A dosage of relugolix of 40 mg once per day has been found to suppress estradiol levels to postmenopausal levels (<20 pg/mL) within 24 hours in premenopausal women. In the control group of women, estradiol levels fluctuated between 50 and 250 pg/mL. Estradiol levels have been found to return to normal concentrations within 4 weeks of discontinuation of relugolix in premenopausal women. The medication additionally suppresses levels of progesterone, luteinizing hormone, and follicle-stimulating hormone in premenopausal women. Relugolix at a dosage of 40 mg or more once per day has been found to reduce testosterone levels to sustained castrate levels (<20 ng/dL) in men. It additionally suppresses luteinizing hormone and follicle-stimulating hormone levels in men. Lower doses of relugolix (<40 mg/day) are under investigation for achieving partial sex hormone suppression in the treatment of endometriosis and uterine fibroids. This is intended to reduce the incidence and severity of menopausal symptoms such as hot flushes and decreased bone mineral density that are secondary to estrogen deficiency.
=== Prime Ministers === Prime Minister for Bosnia and Herzegovina (part of Yugoslav Government) Rodoljub Čolaković (7 March 1945 – 27 April 1945) Prime Ministers Rodoljub Čolaković (27 April 1945 – September 1948) Đuro Pucar (September 1948 – March 1953) Chairmen of the Executive Council Đuro Pucar (March 1953 – December 1953) Avdo Humo (December 1953 – 1956) Osman Karabegović (1956–1963) Hasan Brkić (1963–1965) Rudi Kolak (1965–1967) Branko Mikulić (1967–1969) Dragutin Kosovac (1969 – April 1974) Milanko Renovica (April 1974 – 28 April 1982) Seid Maglajlija (28 April 1982 – 28 April 1984) Gojko Ubiparip (28 April 1984 – April 1986) Josip Lovrenović (April 1986 – April 1988) Marko Ceranić (April 1988 – 20 December 1990) Jure Pelivan (20 December 1990 – 8 April 1992)
===== Light collector ===== Using graphene as a photoactive material requires its bandgap to be 1.4–1.9 eV. In 2010, single cell efficiencies of nanostructured graphene-based PVs of over 12% were achieved. According to P. Mukhopadhyay and R. K. Gupta organic photovoltaics could be "devices in which semiconducting graphene is used as the photoactive material and metallic graphene is used as the conductive electrodes". In 2008, chemical vapor deposition produced graphene sheets by depositing a graphene film made from methane gas on a nickel plate. A protective layer of thermoplastic is laid over the graphene layer and the nickel underneath is then dissolved in an acid bath. The final step is to attach the plastic-coated graphene to a flexible polymer sheet, which can then be incorporated into a PV cell. Graphene/polymer sheets range in size up to 150 square centimeters and can be used to create dense arrays. Silicon generates only one current-driving electron for each photon it absorbs, while graphene can produce multiple electrons. Solar cells made with graphene could offer 60% conversion efficiency.
Sources: en.wikipedia.org
== Latent TGF-β complex == All three TGF-βs are synthesized as precursor molecules containing a propeptide region in addition to the TGF-β homodimer. After it is synthesized, the TGF-β homodimer interacts with a latency-associated peptide (LAP), a protein derived from the N-terminal region of the TGF-β gene product, forming a complex called small latent complex (SLC). This complex remains in the cell until it is bound by another protein called Latent TGF-β-Binding Protein (LTBP), forming a larger complex called large latent complex (LLC). It is this LLC that gets secreted to the extracellular matrix (ECM). In most cases, before the LLC is secreted, the TGF-β precursor is cleaved from the propeptide but remains attached to it by noncovalent bonds. After its secretion, it remains in the extracellular matrix as an in activated complex containing both the LTBP and the LAP which need to be further processed in order to release active TGF-β. The attachment of TGF-β to the LTBP is by disulfide bond which allows it to remain inactive by preventing it from binding to its receptors . Because different cellular mechanisms require distinct levels of TGF-β signaling, the inactive complex of this cytokine gives opportunity for a proper mediation of TGF-β signaling. There are four different LTBP isoforms known, LTBP-1, LTBP-2, LTBP-3 and LTBP-4. Mutation or alteration of LAP or LTBP can result in improper TGF-β signaling. Mice lacking LTBP-3 or LTBP-4 demonstrate phenotypes consistent to phenotypes seen in mice with altered TGF-β signaling.
== Arthropathies and related disorders (710–719) == 710 Diffuse diseases of connective tissue 710.0 Systemic lupus erythematosus 710.2 Sjögren's syndrome 710.3 Dermatomyositis 710.4 Polymyositis 710.5 Eosinophilia myalgia syndrome 710.9 Connective tissue disease, unspec. 711 Arthropathy associated with infections 712 Crystal arthropathies 712.1 Chondrocalcinosis due to dicalcium phosphate crystals 712.2 Chondrocalcinosis due to pyrophosphate crystals 712.3 Chondrocalcinosis, cause unspecified pseudogout 712.8 Other specified crystal arthropathies 712.9 Unspecified crystal arthropathy 713 Arthropathy, endocrine disorders 713.1 Arthropathy, gastrointestinal conditions 714 Rheumatoid arthritis and other inflammatory polyarthropathies 714.0 Rheumatoid arthritis 714.3 Polyarticular juvenile rheumatoid arthritis 715 Osteoarthrosis and allied disorders 715.09 Osteoarthrosis, generalized, multiple sites 715.11 Osteoarthrosis, shoulder 715.14 Osteoarthrosis, hand 715.15 Osteoarthrosis, hip 715.16 Osteoarthrosis, knee 715.17 Osteoarthrosis, ankle/foot 715.9 Osteoarthrosis, unspec. 716 Other and unspecified arthropathies 716.1 Arthropathy, traumatic, unspec. 716.9 Arthropathy, unspec. 717 Internal derangement of knee 717.1 Derangement of anterior horn of medial meniscus 717.42 Derangement of lateral meniscus 717.7 Chondromalacia of patella 717.9 Derangement, internal, knee, unspec.
Treatments used in children are primarily lifestyle interventions and behavioral techniques, although efforts to increase activity in children have had little success. In the United States, medications are not FDA approved for use in this age group. Brief weight management interventions in primary care (e.g. delivered by a physician or nurse practitioner) have only a marginal positive effect in reducing childhood overweight or obesity. Multi-component behaviour change interventions that include changes to dietary and physical activity may reduce BMI in the short term in children aged 6 to 11 years, although the benefits are small and quality of evidence is low.
== Method == SISCAPA is an extension of the well-known gold-standard methods of stable-isotope dilution for quantitation of small molecules by mass spectrometry (MS). Rather than measure an intact protein directly by mass spectrometry, SISCAPA makes use of proteolytic digestion (e.g., with the enzyme trypsin) to cleave sample proteins into smaller peptides ideally suited to quantitation by mass spectrometry. By selecting a target peptide whose sequence occurs only in the selected target protein (a so-called “proteotypic” peptide), the target peptide can serve as a direct quantitative surrogate for the target protein (assuming the digestion process is complete, or at least reproducible). A synthetic version of the target peptide containing a stable isotope label is added in a known amount to the digested sample to serve as an internal standard (SIS). Since the target peptide and SIS are chemically indistinguishable throughout the workflow, but can be measured separately by a mass spectrometer due to the mass difference of the stable isotope label, their ratio provides the desired quantitative estimate of the target peptide amount. The SISCAPA workflow adds a specific enrichment step to the isotope dilution method in which a selected target peptide, together with its associated SIS internal standard, is captured by a sequence-specific anti-peptide antibody.
== External links == "Relaxin Family Peptide Receptors: RXFP3". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived from the original on 2016-03-03. Retrieved 2008-12-09. This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Sources: en.wikipedia.org
== Other research == In October 2021, Relief announced that its collaboration partner, Texas-based Acer Therapeutics, had successfully filed for a New Drug Application with US FDA for their drug ACER-001, for the treatment of Urea Cycle Disorders (UCDs) and Maple syrup urine disease. In September 2021, APR launched a chewable tablet for the treatment of Phenylketonuria, called PKU GOLIKE KRUNCH, in Germany and Italy. APR are also developing Nexodyn, a drug which aids in the management of hard-to-heal ulcers requiring long periods of treatment. Relief is actively developing RLF-100 for non-COVID-19 related acute and chronic lung diseases, such as Pulmonary sarcoidosis.
Next to the Turin Cathedral stand the Palatine Towers, an ancient Roman-medieval structure that served as one of four Roman city gates along the city walls of Turin. This gate allowed access from north to the cardo maximus, the typical second main street of a Roman town. The Palatine Towers are among the best preserved Roman remains in northern Italy. Close to this site, the 51,300 m2 (552,189 sq ft) Piazza della Repubblica plays host to the biggest open market in Europe, locally known as mercato di Porta Palazzo (Porta Palazzo or Porta Pila are the historical and local names of this area).
=== 9 January === Russia and Ukraine conducted their 36th prisoner swap of the conflict, with each side trading 50 POWs to the other. Ukraine's regional prosecutor's office claimed that an S-300 fired from Belgorod Oblast hit a market in Shevchenkove, killing two women, wounding a child, and damaging a shopping centre. A spokesperson stated that Germany had no plans to provide the Leopard 2 to Ukraine.
The end point of translational research in medicine is the production of a promising new treatment that can be used clinically. Translational research is conceived due to the elongated time often taken to bring to bear discovered medical idea in practical terms in a health system. It is for these reasons that translational research is more effective in dedicated university science departments or isolated, dedicated research centers. Since 2009, the field has had specialized journals, the American Journal of Translational Research and Translational Research dedicated to translational research and its findings. Translational research in biomedicine is broken down into different stages. In a two-stage model, T1 research, refers to the "bench-to-bedside" enterprise of translating knowledge from the basic sciences into the development of new treatments and T2 research refers to translating the findings from clinical trials into everyday practice, although this model is actually referring to the 2 "roadblocks" T1 and T2. Waldman et al. propose a scheme going from T0 to T5. T0 is laboratory (before human) research. In T1-translation, new laboratory discoveries are first translated to human application, which includes phase I & II clinical trials. In T2-translation, candidate health applications progress through clinical development to engender the evidence base for integration into clinical practice guidelines. This includes phase III clinical trials. In T3-translation, dissemination into community practices happens.
Sources: en.wikipedia.org
Solid powder is held frozen at -20 °C or below in a desiccated container. Reconstituted solutions are refrigerated and used within a limited period.
Reversed-phase liquid chromatography separates the peptide from related impurities. Mass spectrometry confirms molecular mass, which supports structural identity.
Repeated freezing and thawing can promote aggregation and precipitation of peptide material. Dividing material into single-use aliquots reduces this risk.
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.